<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="556">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>19/10/2005</approvaldate>
  <actrnumber>ACTRN12605000665639</actrnumber>
  <trial_identification>
    <studytitle>A multi-centre, randomised, controlled trial of bronchoalveolar lavage (BAL) directed therapy in young children with cystic fibrosis (CF).</studytitle>
    <scientifictitle>A multi-centre, randomised, controlled trial of bronchoalveolar lavage (BAL) directed therapy to improve clinical outcomes in young children with cystic fibrosis.</scientifictitle>
    <utrn />
    <trialacronym>ACF BAL Study</trialacronym>
    <secondaryid>ACF BAL Study</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This study is designed to examine: 1.The clinical value, safety and cost effectiveness of flexible bronchoscopy (FB) and bronchoalveolar lavage (BAL) to identify lower respiratory tract infection (especially Pseudomonas aeruginosa (Pa)) in infants and young children with cystic fibrosis (CF) and to direct therapy in an attempt to eradicate proven early lung infection and delay progressive lung disease. 2. The role of and relationship between lower respiratory infection and inflammation in the development and pathophysiology of lung disease in a large cohort of CF infants recruited prospectively and followed longitudinally.</interventions>
    <comparator>Standard therapy based on clinical status and oropharyngeal specimen culture</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Prevalence of P. aeruginosa on bronchoalveolar lavage (BAL)</outcome>
      <timepoint>Primary outcomes for all children are measured at age 5 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>High-resolution computerised tomography (HRCT) scan of the chest (Total score)</outcome>
      <timepoint>Primary outcomes for all children are measured at age 5 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nutritional and clinical parameters and lung function for all children + components of HRCT scores</outcome>
      <timepoint>At age 5 years. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Detailed health economic assessment is also being undertaken at this time.</outcome>
      <timepoint>At age 5 years.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All infants diagnosed with cystic fibrosis through the neonatal screening program in Queensland, New South Wales, South Australia, Victoria, Auckland and North Auckland Infants diagnosed with meconium ileus may be enrolled when diagnosis of cystic fibrosis is confirmed. A diagnosis of cystic fibrosis must be confirmed with a positive sweat chloride (Gibson Cooke with a chloride &gt; 60mmol/l).Informed consent from parents or guardians.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>6</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Informed consent cannot be obtained. Infant is severely ill at the time of diagnosis and requires ventilatory support. Family are planning to move overseas in the next few years.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The randomisation key is concealed and held at the Clinical Epidemiology and Biostatistics Unit (CEBU), Royal Children's Hospital, Melbourne.</concealment>
    <sequence>CEBU staff used the next number in sequence on the preprepared randomisation lists generated by computer software Stata. Participants were randomised in blocks by CF Centre and gender to each treatment arm after obtaining informed parental consent.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>18/11/1999</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>165</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>NHMRC</primarysponsorname>
    <primarysponsoraddress>GPO Box 1421
Canberra ACT 2601</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC grant</fundingname>
      <fundingaddress>Canberra</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Children's Hospital Foundation</fundingname>
      <fundingaddress>Royal Children's Hospital, Brisbane</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>The only support from Novartis Pharmaceuticals was the supply of TOBI and nebuliser masks during the study</sponsorname>
      <sponsoraddress>North Ryde NSW</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>1.	This study will examine the use and safety of FB and BAL to identify lower respiratory tract infection (especially PA) in infants and young children with CF and direct therapy in an attempt to eradicate proven early lung infection.  
2.	The role of infection and inflammation in the development of CF lung disease will be examined in a large cohort of CF infants recruited prospectively and followed longitudinally.   
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Children's Hospital</ethicname>
      <ethicaddress>Brisbane</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Children's Hospital</ethicname>
      <ethicaddress> Melbourne</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Children's Hospital at Westmead</ethicname>
      <ethicaddress>Sydney</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress>Melbourne</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Women's and Children's Hospital</ethicname>
      <ethicaddress>Adelaide</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Children's Hospital</ethicname>
      <ethicaddress>Brisbane</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>John Hunter Hospital</ethicname>
      <ethicaddress>Newcastle</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Starship Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>28/05/1998</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Claire Wainwright</name>
      <address>5a Dept. of Respiratory &amp; Sleep Medicine
Lady Cilento Children's Hospital
Stanley Street
South Brisbane 4101</address>
      <phone>+617 3068 1111</phone>
      <fax>+617 3068 2309</fax>
      <email>Claire.Wainwright@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Ms Joyce Cheney</name>
      <address>5a Dept. of Respiratory &amp; Sleep Medicine
Lady Cilento Children's Hospital
Stanley Street
South Brisbane 4101</address>
      <phone>+617 3069 7195</phone>
      <fax>+617 3068 2309</fax>
      <email>Joyce.Cheney@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Joyce Cheney</name>
      <address>5a Dept. of Respiratory &amp; Sleep Medicine
Lady Cilento Children's Hospital
Stanley Street
South Brisbane 4101</address>
      <phone>+ 617 30697195</phone>
      <fax>+ 617 3068 2309</fax>
      <email>Joyce.Cheney@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Claire Wainwright</name>
      <address>5a Dept. of Respiratory &amp; Sleep Medicine
Lady Cilento Children's Hospital
Stanley Street
South Brisbane 4101</address>
      <phone>+617 3068 1111</phone>
      <fax>+61 7 3068 2309</fax>
      <email>Claire.Wainwright@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>